Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
This article was originally published in The Pink Sheet Daily
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.
You may also be interested in...
With a pair of Phase III failures for its major depression disorder candidate ALKS-5461, Alkermes is pinning hopes on a third pivotal trial plus ad hoc analysis of a failed study – a strategy analysts find unlikely to prevail.
Long-acting injectable aripiprazole lauroxil cleared six weeks late, but Alkermes is happy with label's flexibility on dosing, saying product will be differentiated from Abilify Maintena.
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.